Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients

Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2009, Pages 185-195

  Sam, Wai Johnn ^a   Akhlaghi, Fatemeh ^a   Rosenbaum, Sara E ^a,b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Acyl MPAG; Enterohepatic recirculation; GFR; MPAG; Mycophenolic acid; NONMEM; Population pharmacokinetics; Renal transplant

Indexed keywords

7 O MYCOPHENOLIC ACID GLUCURONIDE; CYCLOSPORIN A; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID ACYL GLUCURONIDE; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; COMPARTMENT MODEL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; INTERINDIVIDUAL VARIABILITY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; GLUCURONIDES; HUMANS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 58849103434     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008329558     Document Type: Article

References (26)

1. Mele TS, Halloran PF The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 2000 ; 47: 215-245.
2. Nowak I., Shaw LM Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995 ; 41: 1011-1017.
3. Mackenzie PI Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit. 2000 ; 2000: 10-13.
4. Bullingham RE, Nicholls AJ, Kamm BR Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998 ; 34: 429-455.
5. Sugioka N., Sasaki T., Kokuhu T., et al. Clinical pharmacokinetics of mycophenolate mofetil in Japanese renal transplant recipients: a retrospective cohort study in a single center. Biol Pharm Bull. 2006 ; 29: 2099-2105.
6. Tedesco-Silva H., Bastien MC, Choi L., et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc. 2005 ; 37: 852-855.
7. Shipkova M., Armstrong VW, Wieland E., et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999 ; 126: 1075-1082.
8. Shipkova M., Armstrong VW, Weber L., et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit. 2002 ; 24: 390-399.
9. Patel CG, Richman K., Yang D., Yan B., Gohh RY, Akhlaghi F. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther Drug Monit. 2007 ; 29: 735-742.
10. Soman RS, Zahir H., Akhlagh IF Development and validation of an HPLC-UV method for determination of iohexol in human plasma. J Chromatogr B. 2005 ; 816: 339-343.
11. Patel CG, Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit. 2006 ; 28: 116-122.
12. Beal SL, Sheiner LB NONMEM Users Guide. San Francisco: NONMEM Project Group, University of California, San Francisco ; 1992.
13. Hofmann AF, Molino G., Milanese M., Belforte G. Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man: cholic acid in healthy man. J Clin Invest. 1983 ; 71: 1003-1022.
14. Mandema JW, Verotta D., Sheiner LB Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm. 1992 ; 20: 511-528.
15. Shum B., Duffull SB, Taylor PJ, Tett SE Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003 ; 56: 188-197.
16. van Hest RM, van Gelder T., Vulto AG, Mathot RAA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005 ; 44: 1083-1096.
17. Johnson HJ, Swan SK, Heim-Duthov KL, Nicholls AJ, Tsina I., Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther. 1998 ; 63: 512-518.
18. van Hest RM, Mathot RAA, Pescovitz MD, Gordon R., Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006 ; 17: 871-880.
19. Cremers S., Schoemaker R., Scholten E., et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol. 2005 ; 60: 249-256.
20. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol. 1999 ; 10: 1143-1148.
21. Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos. 2006 ; 34: 261-266.
22. Saitoh H., Kobayashi M., Oda M., Nakasato K., Kobayashi M., Tadano K. Characterization of intestinal absorption and enterohepatic circulation of mycophenolic acid and its 7-O-glucuronide in rats. Drug Metab Pharmacokinet. 2006 ; 21: 406-413.
23. Wolff NA, Burckhardt BC, Burckhardt G., Oellerich M., Armstrong VW Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol Dial Transplant. 2007 ; 22: 2497-2503.
24. Sakurai Y., Motohashi H., Ueo H., et al. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 ; 21: 61-67.
25. Shaw LM, Korecka M., DeNofrio D., Brayman KL Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001 ; 34: 17-22.
26. Pillans PI, Rigby RJ, Kubler P., et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem. 2001 ; 34: 77-81.